NeoGenomics Down 22.8%, RSI 26.14 Signals Oversold, EPS Estimates Up 14.8%
NeoGenomics shares have dropped 22.8% over the past four weeks and now show an RSI reading of 26.14, indicating potential oversold conditions. Analysts have raised 2026 EPS estimates by 14.8% in the last month and the stock holds a Zacks Rank #2 Buy rating, suggesting possible near-term rebounds.
1. Four-Week Decline and Oversold Indicator
NeoGenomics shares tumbled 22.8% over four weeks, driving the Relative Strength Index (RSI) to 26.14. This reading falls below the typical oversold threshold of 30 and suggests the current selling pressure may be overextended.
2. RSI Mechanics and Limitations
The RSI gauges momentum by measuring price speed and change on a zero-to-100 scale, with readings under 30 signaling oversold levels. While useful for spotting potential reversals, RSI should be complemented by fundamental and broader technical analysis.
3. Analyst Estimate Revisions
In the past 30 days, sell-side analysts have raised 2026 EPS forecasts by 14.8%, reflecting growing confidence in earnings performance. Coupled with a Zacks Rank #2 Buy rating, these upward revisions support the case for a near-term stock rebound.